Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 16, 2026 | June 17, 2026 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | President and CSO | December 28, 2020 | December 30, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 676,900 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 63,481 · Balance 676,900 F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
Korsana Biosciences, Inc.
Report date December 28, 2020 · Filed December 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 251,648 |
Reported balance
After 2020-12-28 transaction · row 1
1 source rowRow 1 · 2020-12-28 · Sale · Disposed 20,107 · Balance 251,648 F1: The proceeds from the sale are intended to cover income taxes arising out of prior stock option exercises, including those in which the reporting person held the underlying shares. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.94 to $3.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The proceeds from the sale are intended to cover income taxes arising out of prior stock option exercises, including those in which the reporting person held the underlying shares.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.94 to $3.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 17, 2026 20:44 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 63,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274288 · ownership.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 676,900 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:27 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085440 · ownership.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613,419 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 24,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076206 · ownership.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 568,419 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:26 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039132 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,108 F1 · kind: The restricted stock, granted pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 20:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 70,000 | $11.78 | $824,600.00 |
DisclosureSEC source: 0001209191-22-045808 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,758 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.64 to $11.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 190,383 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0001209191-22-035443 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 190,383 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, vested as to 1.25% on each monthly anniversary of the vesting commencement date for the first 36 months, and as to 4.5833% of the award on each monthly anniversary thereafter, is presently exercisable in full. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 190,383 | $12.01 | $2,286,499.83 |
DisclosureSEC source: 0001209191-22-035443 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,758 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 190,383 | $11.65 | $2,217,961.95 |
DisclosureSEC source: 0001209191-22-035443 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033983 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,758 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:10 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 23,571 | $11.59 | $273,187.89 |
DisclosureSEC source: 0001209191-21-040892 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,187 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.47 to $11.77, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038179 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,758 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 18:14 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | SaleCommon Stock | 20,107 | $3.01 | $60,522.07 |
DisclosureSEC source: 0001140361-20-029869 · form4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,648 F1 · shares: The proceeds from the sale are intended to cover income taxes arising out of prior stock option exercises, including those in which the reporting person held the underlying shares. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.94 to $3.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034692 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,992 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 21:43 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $9.12 | $0.00 |
DisclosureSEC source: 0001209191-20-004855 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,707 Underlying: Class A Common Stock · 60,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 21:43 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 60,000 | $12.59 | $755,400.00 |
DisclosureSEC source: 0001209191-20-004855 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,272 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 21:43 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 60,000 | $9.12 | $547,200.00 |
DisclosureSEC source: 0001209191-20-004855 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 22:23 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001209191-20-004301 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,888 shares Expires 2020-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 22:23 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 8,888 | $12.80 | $113,766.40 |
DisclosureSEC source: 0001209191-20-004301 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,272 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.74 to $12.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 22:23 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 8,888 | $10.02 | $89,057.76 |
DisclosureSEC source: 0001209191-20-004301 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 22:55 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | SaleCommon Stock | 25,000 | $2.48 | $62,000.00 |
DisclosureSEC source: 0001209191-19-062322 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,755 F1 · shares: The proceeds from the sale are intended to cover income taxes arising out of prior stock option exercises, including those in which the reporting person held the underlying shares. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.38 to $2.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 22:55 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | SaleCommon Stock | 25,000 | $2.55 | $63,750.00 |
DisclosureSEC source: 0001209191-19-062322 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,755 F1 · shares: The proceeds from the sale are intended to cover income taxes arising out of prior stock option exercises, including those in which the reporting person held the underlying shares. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.58, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 21:38 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GiftClass A Common Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061136 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,272 Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:38 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GiftClass A Common Stock | 1,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061136 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,772 Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 22:43 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-19-058163 · doc4.xml · derivative · entry 1 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-11-22 F1 · derivative.exercise_date: The stock option grant will vest and become exercisable upon the attainment of both performance-based and service-based hurdles, as follows: (i) 20% of the shares subject to the option, if the average closing price of the common stock reported by Nasdaq for any thirty (30) consecutive trading days equals or exceeds $10; plus an additional (ii) 40% of the shares, if the average closing price equals or exceeds $20; plus an additional (iii) 40% of the shares, if the average closing price equals or exceeds $30; in each case, subject to the continuous employment or service through the later of the date that the performance hurdles set forth above are attained (but no later than December 31, 2024) and December 31, 2021. F2 · derivative.expiration_date: To the extent unvested as of December 31, 2024, all unvested shares underlying such performance-based option will be cancelled. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033615 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,609 F1 · kind: The restricted stock, granted pursuant to the director compensation policy, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 10, 2019 Filed May 14, 2019 20:10 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 4,055 | $10.53 | $42,699.15 |
DisclosureSEC source: 0001209191-19-029601 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,903 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on July 31, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $10.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock | 270,107 | $14.81 | $4,000,284.67 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,755 Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 514,786 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 13 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,786 Underlying: Common Stock · 514,786 shares Expires 2029-01-29 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F8 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 141,007 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 12 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,007 Underlying: Common Stock · 141,007 shares Expires 2028-02-21 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 113,430 | $0.00 Strike: $18.46 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 11 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,430 Underlying: Common Stock · 113,430 shares Expires 2027-02-27 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F6 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2017. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,801 | $0.00 Strike: $11.28 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 10 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,801 Underlying: Common Stock · 50,801 shares Expires 2026-03-01 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F5 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2016. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 9 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-03-16 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F4 · derivative.exercise_date: This option to purchase 25,212 shares vests in equal installments upon achievement of certain regulatory and commercial milestones. The option has vested as to 2,500 shares as of the date hereof. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 13,125 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 8 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 13,125 shares Expires 2025-03-16 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,930 | $0.00 Strike: $15.54 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 7 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,930 Underlying: Common Stock · 9,930 shares Expires 2024-03-03 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 27,773 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 6 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,773 Underlying: Common Stock · 27,773 shares Expires 2023-02-01 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,491 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 5 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,491 Underlying: Common Stock · 17,491 shares Expires 2022-02-01 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 37,286 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 4 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,286 Underlying: Common Stock · 37,286 shares Expires 2021-02-01 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 888 | $0.00 Strike: $12.39 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888 Underlying: Common Stock · 888 shares Expires 2020-02-02 F2 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 51,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023521 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,648 F1 · shares: In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received Cyclerion shares representing an equitable adjustment of Ironwood shares held by the reporting person prior to the Separation. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 562,500 | Not disclosed Strike: $11.49 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 12 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Class A Common Stock · 562,500 shares Expires 2029-01-29 F8 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F12 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 147,813 | Not disclosed Strike: $12.95 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 11 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,187 Underlying: Class A Common Stock · 147,813 shares Expires 2028-02-21 F8 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F11 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 109,375 | Not disclosed Strike: $14.93 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 10 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,625 Underlying: Class A Common Stock · 109,375 shares Expires 2027-02-27 F8 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F10 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 44,063 | Not disclosed Strike: $9.12 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 9 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,707 Underlying: Class A Common Stock · 44,063 shares Expires 2026-03-01 F8 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F9 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2016. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 1,771 | Not disclosed Strike: $12.56 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 8 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,229 Underlying: Class A Common Stock · 1,771 shares Expires 2024-03-03 F7 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 1,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 83,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F7 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 1,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 83,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F7 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 1,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 83,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 9,617 | Not disclosed Strike: $11.65 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 7 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,383 Underlying: Class A Common Stock · 9,617 shares Expires 2023-02-01 F6 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 9,617 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 190,383 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F6 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 9,617 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 190,383 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F6 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 9,617 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 190,383 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 8,029 | Not disclosed Strike: $13.11 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 6 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,971 Underlying: Class A Common Stock · 8,029 shares Expires 2022-02-01 F4 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 8,029 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 101,971 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 8,029 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 101,971 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 8,029 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 101,971 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $15.62 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 5 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires 2025-03-16 F3 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. F3 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. F3 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. F3 · derivative.exercise_date: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 41,041 | Not disclosed Strike: $11.11 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 4 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 41,041 shares Expires 2021-02-01 F3 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. F3 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. F3 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. F3 · derivative.exercise_date: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 20,000 shares Expires 2019-07-28 F3 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. F3 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. F3 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. F3 · derivative.exercise_date: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 2,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 532,958 F2 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.